Advanced search
1 file | 363.21 KB Add to list

Anaphylaxis in pregnancy : a population‐based multinational European study

Author
Organization
Abstract
Anaphylaxis in pregnancy is a rare but severe complication for both mother and infant. Population‐based data on anaphylaxis in pregnancy are lacking from mainland European countries. This multinational study presents the incidence, causative agents, management and maternal and infant outcomes of anaphylaxis in pregnancy. This descriptive multinational study used a combination of retrospective (Finnish medical registries) and prospective population‐based studies (UK, France, Belgium and the Netherlands) to identify cases of anaphylaxis. Sixty‐five cases were identified among 4,446,120 maternities (1.5 per 100,000 maternities; 95%CI 1.1–1.9). The incidence did not vary between countries. Approximately three‐quarters of reactions occurred at the time of delivery. The most common causes were antibiotics in 27 women (43%), and anaesthetic agents in 11 women (17%; including neuromuscular blocking drugs, 7), which varied between countries. Anaphylaxis had very poor outcomes for one in seven mothers and one in seven babies; the maternal case fatality rate was 3.2% (95%CI 0.4–11.0) and the neonatal encephalopathy rate was 14.3% (95%CI 4.8–30.3). Across Europe, anaphylaxis related to pregnancy is rare despite having a multitude of causative agents and different antibiotic prophylaxis protocols.
Keywords
Anesthesiology and Pain Medicine, anaphylaxis causative agents, anaphylaxis in pregnancy, anaphylaxis management, maternal morbidity, neonatal encephalopathy, neuromuscular blocking drugs, OBSTETRIC SURVEILLANCE SYSTEM, GROUP-B STREPTOCOCCUS, LABOR SECONDARY, PROPHYLAXIS, GUIDELINES, ANESTHESIA

Downloads

  • Anae2020-McCallPublishedPaper-McCall.pdf
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • PDF
    • |
    • 363.21 KB

Citation

Please use this url to cite or link to this publication:

MLA
McCall, S. J., et al. “Anaphylaxis in Pregnancy : A Population‐based Multinational European Study.” ANAESTHESIA, 2020, doi:10.1111/anae.15069.
APA
McCall, S. J., Bonnet, M. ‐P., Äyräs, O., Vandenberghe, G., Gissler, M., Zhang, W. H., … the INOSS collaboration, [missing]. (2020). Anaphylaxis in pregnancy : a population‐based multinational European study. ANAESTHESIA. https://doi.org/10.1111/anae.15069
Chicago author-date
McCall, S. J., M. ‐P. Bonnet, O. Äyräs, Griet Vandenberghe, M. Gissler, Wei Hong Zhang, V. Van Leeuw, et al. 2020. “Anaphylaxis in Pregnancy : A Population‐based Multinational European Study.” ANAESTHESIA. https://doi.org/10.1111/anae.15069.
Chicago author-date (all authors)
McCall, S. J., M. ‐P. Bonnet, O. Äyräs, Griet Vandenberghe, M. Gissler, Wei Hong Zhang, V. Van Leeuw, C. Deneux-Tharaux, J. J. Kurinczuk, M. Knight, and [missing] the INOSS collaboration. 2020. “Anaphylaxis in Pregnancy : A Population‐based Multinational European Study.” ANAESTHESIA. doi:10.1111/anae.15069.
Vancouver
1.
McCall SJ, Bonnet M ‐P., Äyräs O, Vandenberghe G, Gissler M, Zhang WH, et al. Anaphylaxis in pregnancy : a population‐based multinational European study. ANAESTHESIA. 2020;
IEEE
[1]
S. J. McCall et al., “Anaphylaxis in pregnancy : a population‐based multinational European study,” ANAESTHESIA, 2020.
@article{8672367,
  abstract     = {Anaphylaxis in pregnancy is a rare but severe complication for both mother and infant. Population‐based data on anaphylaxis in pregnancy are lacking from mainland European countries. This multinational study presents the incidence, causative agents, management and maternal and infant outcomes of anaphylaxis in pregnancy. This descriptive multinational study used a combination of retrospective (Finnish medical registries) and prospective population‐based studies (UK, France, Belgium and the Netherlands) to identify cases of anaphylaxis. Sixty‐five cases were identified among 4,446,120 maternities (1.5 per 100,000 maternities; 95%CI 1.1–1.9). The incidence did not vary between countries. Approximately three‐quarters of reactions occurred at the time of delivery. The most common causes were antibiotics in 27 women (43%), and anaesthetic agents in 11 women (17%; including neuromuscular blocking drugs, 7), which varied between countries. Anaphylaxis had very poor outcomes for one in seven mothers and one in seven babies; the maternal case fatality rate was 3.2% (95%CI 0.4–11.0) and the neonatal encephalopathy rate was 14.3% (95%CI 4.8–30.3). Across Europe, anaphylaxis related to pregnancy is rare despite having a multitude of causative agents and different antibiotic prophylaxis protocols.},
  author       = {McCall, S. J. and Bonnet, M. ‐P. and Äyräs, O. and Vandenberghe, Griet and Gissler, M. and Zhang, Wei Hong and Van Leeuw, V. and Deneux-Tharaux, C. and Kurinczuk, J. J. and Knight, M. and the INOSS collaboration, [missing]},
  issn         = {0003-2409},
  journal      = {ANAESTHESIA},
  keywords     = {Anesthesiology and Pain Medicine,anaphylaxis causative agents,anaphylaxis in pregnancy,anaphylaxis management,maternal morbidity,neonatal encephalopathy,neuromuscular blocking drugs,OBSTETRIC SURVEILLANCE SYSTEM,GROUP-B STREPTOCOCCUS,LABOR SECONDARY,PROPHYLAXIS,GUIDELINES,ANESTHESIA},
  language     = {eng},
  title        = {Anaphylaxis in pregnancy : a population‐based multinational European study},
  url          = {http://dx.doi.org/10.1111/anae.15069},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: